<DOC>
	<DOCNO>NCT00094718</DOCNO>
	<brief_summary>West Nile ( WN ) virus infection emerge disease ; WN infection may lead paralysis , coma , death . The purpose study test safety immune response WN vaccine healthy adult . The vaccine base live attenuate vaccine develop dengue virus .</brief_summary>
	<brief_title>Safety Immune Response West Nile Virus Vaccine ( WN/DEN4-3'delta30 ) Healthy Adults</brief_title>
	<detailed_description>WN widely distribute Africa Europe , usually associate mild illness . In United States , WN consider public health threat severe illness cause WN infection cause paralysis , coma , death , especially elderly . This study evaluate safety immunogenicity live attenuate chimeric virus , WN/DEN4-3'delta30 , derive DEN4 dengue virus wild-type WN serotypes . This study last 180 day . Participants Cohort 1 randomly assign receive low dose WN/DEN4-3'delta30 placebo study entry . Cohort 2 begin safety review participant Cohort 1 . Participants Cohort 2 receive high dose WN/DEN4-3'delta30 placebo . Cohort 3 begin safety review participant Cohort 2 . Participants Cohort 3 receive high dose WN/DEN4-3'delta30 placebo . Immediately receive injection , participant observe 30 minute immediate adverse reaction . After vaccination , participant ask monitor temperature every day 16 day Day 19 . Study visit occur every day vaccination Day 16 , follow 5 additional visit select day Day 180 . Blood collection target physical exam occur study visit . Some participant ask undergo skin biopsy additional blood collection select visit .</detailed_description>
	<mesh_term>Encephalitis</mesh_term>
	<mesh_term>West Nile Fever</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Willing follow duration study Willing use acceptable method contraception Good general health Clinically significant neurologic , cardiac , pulmonary , hepatic , rheumatologic , autoimmune , renal disease Behavioral , cognitive , psychiatric disease , opinion investigator , affect ability volunteer understand cooperate study Hematologic disease History migraine headache History encephalitis Alcohol drug abuse within 12 month prior study entry History severe allergic reaction anaphylaxis Emergency room visit hospitalization severe asthma within 6 month prior study entry HIV1 infect Hepatitis C virus infect Hepatitis B surface antigen positive Known immunodeficiency syndrome Use corticosteroid immunosuppressive drug within 30 day study entry . Participants use topical nasal corticosteroid exclude . Live vaccine within 4 week prior study entry Killed vaccine within 2 week prior study entry Blood product within 6 month prior study entry Participation another investigational vaccine drug trial within 60 day start study , participate study Previously receive licensed experimental yellow fever , tickborne encephalitis , dengue vaccine Surgical removal spleen History West Nile encephalitis History dengue virus infection flavivirus infection ( e.g. , yellow fever virus , St. Louis encephalitis , West Nile virus ) Other condition , opinion investigator , would affect participant 's participation study Pregnancy breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Chimeric Virus Vaccine</keyword>
	<keyword>West Nile Virus</keyword>
	<keyword>Dengue Virus</keyword>
</DOC>